Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann M Buchanan

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Antimicrobial Agents and Chemotherapy|October 25, 2021
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 StudyCindy Vavro, Theodore Ruel, Andrew Wiznia, et al.
The Pediatric Infectious Disease Journal|November 24, 2021
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for ChildrenRajendra P Singh, Kimberly K Adkison, Mark Baker, et al.
British Journal of Clinical Pharmacology|January 15, 2017
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult womenChristine Trezza, Susan L Ford, Elizabeth Gould, et al.
Archives of Disease in Childhood|August 9, 2012
Predicting mortality for paediatric inpatients where malaria is uncommonDana C Clifton, Habib O Ramadhani, Levina J Msuya, et al.
BMC Infectious Diseases|July 25, 2016
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjectsLisa L Ross, Ivy H Song, Niki Arya, et al.
International Journal of Antimicrobial Agents|August 15, 2024
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspectiveAnn M Buchanan, Adrie Bekker, Hardik Chandasana, et al.
The Pediatric Infectious Disease Journal|January 31, 2013
Prevalence of mycobacteremia among HIV-infected infants and children in northern TanzaniaKatherine D Gray, Coleen K Cunningham, Dana C Clifton, et al.
Plos One|February 20, 2014
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysisAnn M Buchanan, Dorothy E Dow, Charles G Massambu, et al.
AIDS (London, England)|May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatricsHardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
The Pediatric Infectious Disease Journal|February 4, 2026
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI ResistanceHardik Chandasana, Ann M Buchanan, Cassidy A Henegar, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Antimicrobial Agents and Chemotherapy|October 25, 2021
Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 StudyCindy Vavro, Theodore Ruel, Andrew Wiznia, et al.
The Pediatric Infectious Disease Journal|November 24, 2021
Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for ChildrenRajendra P Singh, Kimberly K Adkison, Mark Baker, et al.
British Journal of Clinical Pharmacology|January 15, 2017
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult womenChristine Trezza, Susan L Ford, Elizabeth Gould, et al.
Archives of Disease in Childhood|August 9, 2012
Predicting mortality for paediatric inpatients where malaria is uncommonDana C Clifton, Habib O Ramadhani, Levina J Msuya, et al.
BMC Infectious Diseases|July 25, 2016
No clinically significant pharmacokinetic interactions between dolutegravir and daclatasvir in healthy adult subjectsLisa L Ross, Ivy H Song, Niki Arya, et al.
International Journal of Antimicrobial Agents|August 15, 2024
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspectiveAnn M Buchanan, Adrie Bekker, Hardik Chandasana, et al.
The Pediatric Infectious Disease Journal|January 31, 2013
Prevalence of mycobacteremia among HIV-infected infants and children in northern TanzaniaKatherine D Gray, Coleen K Cunningham, Dana C Clifton, et al.
Plos One|February 20, 2014
Progress in the prevention of mother to child transmission of HIV in three regions of Tanzania: a retrospective analysisAnn M Buchanan, Dorothy E Dow, Charles G Massambu, et al.
AIDS (London, England)|May 20, 2024
Bridging dolutegravir clinical viral response across doses and formulations using model-based exposure-response analysis in pediatricsHardik Chandasana, Siobhán Hayes, Ann M Buchanan, et al.
The Pediatric Infectious Disease Journal|February 4, 2026
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI ResistanceHardik Chandasana, Ann M Buchanan, Cassidy A Henegar, et al.
Pageof 3